

✓  
Page 44, please delete all of Table 7a and insert therefor the attached substitute Table 7a.

✓  
Page 45, please delete all of Table 7b and insert therefor the attached substitute Table 7b.

**IN THE CLAIMS:**

Please amend the claims as indicated below. A marked-up copy of the claims is attached.

---

3. Nucleic acid according to Claim 1, which furthermore comprises a CDR2 region, selected from:

- (a) a nucleotide sequence which encodes the amino acid sequence:

DISYSGSTKYKPSLRS, (SEQ ID NO:35)

- (b) a nucleotide sequence which encodes the amino acid sequence:

VISYDGSNKYYADSVKG, (SEQ ID NO:36)

and

- (c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).
-

6. Nucleic acid according to Claim 4, which furthermore comprises a CDR2 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

G S H Q R P S, (SEQ ID NO:41)

(b) a nucleotide sequence which encodes the amino acid sequence:

S N N Q R P S, (SEQ ID NO:42)

and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).

11. Vector, characterized in that it

(a) contains at least one copy of a nucleic acid according to Claim 1 and/or at least one copy of a nucleic acid according to Claim 4 or

(b) contains at least one copy of a nucleic acid according to Claim 7 and/or at least one copy of a nucleic acid according to Claim 9.

12. Cell, characterized in that it

(a) expresses a nucleic acid according to Claim 1 and/or a nucleic acid according to Claim 4 or

(b) a nucleic acid according to Claim 7 and/or a nucleic acid according to Claim 9.

Sub  
C<sup>1</sup>  
B<sup>7</sup>

13. Polypeptide, characterized in that it

- (a) is encoded by a nucleic acid according to Claim 1 and/or a nucleic acid according to Claim 4 or
  - (b) by a nucleic acid according to Claim 7 and/or a nucleic acid according to Claim 9.
- 

B<sup>8</sup>

16. Polypeptide according to Claim 13, characterized in that it is coupled to a labelling group or a toxin.

---

17. Antibody against a polypeptide according to Claim 13.

---

Sub  
C<sup>2</sup>

19. Pharmaceutical composition which comprises, as the active component, a nucleic acid according to Claim 1, a vector according to Claim 11, a cell according to Claim 12, a polypeptide according to Claim 13 or an antibody according to Claim 17, where appropriate together with other active components and pharmaceutically customary adjuvants, additives or excipients.

B<sup>9</sup>

20. Use of a nucleic acid according to Claim 1, of a vector according to Claim 11, of a cell according to Claim 12, of a polypeptide according to Claim 13, of an antibody according to Claim 17, or of a pharmaceutical composition according to Claim 19 for preparing an agent for the diagnosis or for the treatment or prevention of AITP.